Multivariate analysis of prognostic factors in patients with pulmonary actinomycosis

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Park, Ji Y ^a   Lee, Taehoon ^a   Lee, Hongyeul ^a   Lim, Hyo Jeong ^a   Lee, Jinwoo ^b   Park, Jong S ^a   Cho, Young Jae ^a   Park, Young S ^b   Lee, Chang Hoon ^b   Lee, Sang Min ^b   Yoon, Ho I ^a   Yim, Jae Joon ^b   Yoo, Chul Gyu ^b   Kim, Young W ^b   Han, Sung K ^b   Lee, Choon Taek ^a   Lee, Jae H ^a  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Actinomycosis; Anti bacterial agents; Prognostic factors; Pulmonary; Treatment outcome

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CLINDAMYCIN; SULTAMICILLIN; ANTIINFECTIVE AGENT;

ACTINOMYCOSIS; AGE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENDER; HEMOPTYSIS; HISTOPATHOLOGY; HUMAN; LUNG ACTINOMYCOSIS; LUNG INFECTION; LUNG PARENCHYMA; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIVARIATE ANALYSIS; PROGNOSIS; RECURRENT INFECTION; RELAPSE; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; AGED; INTRAVENOUS DRUG ADMINISTRATION; LUNG DISEASES; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RECURRENT DISEASE;

ACTINOMYCOSIS; ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; AGED; ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84892180862     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-10     Document Type: Article

References (20)

1. Wong VK, Turmezei TD, Weston VC. Actinomycosis. BMJ 2011, 343:d6099. 10.1136/bmj.d6099, 21990282.
2. Russo TA. Agents of actinomycosis. Principles and Practice of Infectious Diseases 2010, 3209-3219. Philadelphia: Elsevier, Churchill Livingstone, Mandell GL, 7.
3. Mabeza GF, Macfarlane J. Pulmonary actinomycosis. Eur Respir J 2003, 21(3):545-551. 10.1183/09031936.03.00089103, 12662015.
4. Smego RA, Foglia G. Actinomycosis. Clin Infect Dis 1998, 26(6):1255-1261. quiz 1262-1253, 10.1086/516337, 9636842.
5. Weese WC, Smith IM. A study of 57 cases of actinomycosis over a 36-year period. A diagnostic 'failure' with good prognosis after treatment. Arch Intern Med 1975, 135(12):1562-1568. 10.1001/archinte.1975.00330120040006, 1200725.
6. Song JU, Park HY, Jeon K, Um SW, Kwon OJ, Koh WJ. Treatment of thoracic actinomycosis: a retrospective analysis of 40 patients. Ann Thorac Med 2010, 5(2):80-85. 10.4103/1817-1737.62470, 2883202, 20582172.
7. Harvey JC, Cantrell JR, Fisher AM. Actinomycosis: its recognition and treatment. Ann Intern Med 1957, 46(5):868-885.
8. Peabody JW, Seabury JH. Actinomycosis and nocardiosis. A review of basic differences in therapy. Am J Med 1960, 28:99-115. 10.1016/0002-9343(60)90226-6, 14431196.
9. Hsieh MJ, Liu HP, Chang JP, Chang CH. Thoracic actinomycosis. Chest 1993, 104(2):366-370. 10.1378/chest.104.2.366, 8339619.
10. Choi J, Koh WJ, Kim TS, Lee KS, Han J, Kim H, Kwon OJ. Optimal duration of IV and oral antibiotics in the treatment of thoracic actinomycosis. Chest 2005, 128(4):2211-2217.
11. Kim TS, Han J, Koh WJ, Choi JC, Chung MJ, Lee JH, Shim SS, Chong S. Thoracic actinomycosis: CT features with histopathologic correlation. AJR Am J Roentgenol 2006, 186(1):225-231. 10.2214/AJR.04.1749, 16357406.
12. Kolditz M, Bickhardt J, Matthiessen W, Holotiuk O, Hoffken G, Koschel D. Medical management of pulmonary actinomycosis: data from 49 consecutive cases. J Antimicrob Chemother 2009, 63(4):839-841. 10.1093/jac/dkp016, 19218569.
13. Baik JJ, Lee GL, Yoo CG, Han SK, Shim YS, Kim YW. Pulmonary actinomycosis in Korea. Respirology 1999, 4(1):31-35. 10.1046/j.1440-1843.1999.00152.x, 10339728.
14. Boudaya MS, Smadhi H, Marghli A, Mouna M, Charmiti F, Ismail O, Kilani T. Surgery in thoracic actinomycosis. Asian Cardiovasc Thorac Ann 2012, 20(3):314-319. 10.1177/0218492312439310, 22718721.
15. Hansen JM, Fjeldsoe-Nielsen H, Sulim S, Kemp M, Christensen JJ. Actinomyces species: a Danish survey on human infections and microbiological characteristics. Open Microbiol J 2009, 3:113-120. 10.2174/1874285800903010113, 2720514, 19657460.
16. Smith AJ, Hall V, Thakker B, Gemmell CG. Antimicrobial susceptibility testing of actinomyces species with 12 antimicrobial agents. J Antimicrob Chemother 2005, 56(2):407-409. 10.1093/jac/dki206, 15972310.
17. Brook I. Actinomycosis: diagnosis and management. South Med J 2008, 101(10):1019-1023. 10.1097/SMJ.0b013e3181864c1f, 18791528.
18. Payne DJ, Cramp R, Winstanley DJ, Knowles DJ. Comparative activities of clavulanic acid, sulbactam, and tazobactam against clinically important beta-lactamases. Antimicrob Agents Chemother 1994, 38(4):767-772. 10.1128/AAC.38.4.767, 284540, 8031044.
19. Henry FC. Penicillins and β-Lactam Inhibitors. Principles and Practice of Infectious Diseases 2010, 309-322. Philadelphia: Elsevier, Churchill Livingstone, Mandell GL, 7.
20. Slade PR, Slesser BV, Southgate J. Thoracic actinomycosis. Thorax 1973, 28(1):73-85. 10.1136/thx.28.1.73, 469994, 4568119.